David Enloe, CEO of Ajinomoto Bio-Pharma Services, is getting his company in shape for future acquisitions. He recently expanded his company’s San Diego facilities.

David Enloe, CEO of Ajinomoto Bio-Pharma Services, is getting his company in shape for future acquisitions. He recently expanded his company’s San Diego facilities. Photo by Jamie Scott Lytle.

Japanese food and drug manufacturing giant Ajinomoto Group is reorganizing, placing three disparate drug-making businesses on three continents under one umbrella...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129